Piyush Goyal Invites Global Pharma Companies; Says Industry Can Double in Five Years

📌 Summary:

• Commerce & Industry Minister Piyush Goyal invited global pharma companies to partner India, saying the ~$60 billion pharma industry can double in five years — moving beyond generics toward innovation while keeping medicines affordable
• India's economy grew 7.7% (year ended March 2026), remaining the fastest-growing large economy despite the Ukraine/West Asia conflicts and US 50% tariffs
• Three pillars cited — Trust, Innovation, Partnerships: GMP aligned to global benchmarks; ~65–70% of WHO vaccine needs sourced from India; 10 of the world's 25 largest generic firms operate from India; India has the most US-FDA-approved plants outside the US
• Innovation: patent filings up ~100%; the Biopharma Shakti programme launched; a $10 billion programme to support innovation; generics are 80–90% of US medicine volume but only ~10–15% of value (affordability)
• Trade: India has signed nine FTAs covering 50+ countries, with preferential/zero-duty access for many pharma products

🎯 UPSC Relevance: GS3 economy — manufacturing, the pharmaceutical sector, FTAs, innovation and value-addition, and India's place in global supply chains.

📝 Prelims Facts:

• India's pharma industry is currently ~$60 billion; GDP grew 7.7% in the year ended March 2026
• GDRC 2026 = Global Drug Regulators Conclave; IPHEX = International Pharma and Healthcare Expo
• Biopharma Shakti is a programme to promote pharmaceutical innovation

🔑 Key Term: Good Manufacturing Practices (GMP) — globally benchmarked quality-assurance standards ensuring medicines are consistently produced and controlled to required quality.